BCL‐2 inhibitors are also in widespread use in other hematological malignancies, and a specific PP2A inhibitor, LB‐100, is currently in use for solid oncology tumors, undergoing a phase 1b/2 clinical trial (NCT03886662). This evidence concerns the gene BCL2 and cancer.